Guselkumab Continues Winning Streak in Crohn's Disease

Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials

Related Keywords

Fort Pierce ,Florida ,United States ,Houston ,Texas ,Washington ,Ed Susman ,Md Anderson Cancer Center ,Johnson ,Disease Week ,Cancer Center ,Disease Activity Index ,Stool Frequency ,Abdominal Pain ,